日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Differences in Stability, Activity and Mutation Effects Between Human and Mouse Leucine-Rich Repeat Kinase 2

人类和小鼠富亮氨酸重复激酶2在稳定性、活性和突变效应方面的差异

Langston, Rebekah G; Rudenko, Iakov N; Kumaran, Ravindran; Hauser, David N; Kaganovich, Alice; Ponce, Luis Bonet; Mamais, Adamantios; Ndukwe, Kelechi; Dillman, Allissa A; Al-Saif, Amr M; Beilina, Aleksandra; Cookson, Mark R

The function of orthologues of the human Parkinson's disease gene LRRK2 across species: implications for disease modelling in preclinical research

人类帕金森病基因LRRK2同源基因在不同物种中的功能:对临床前研究中疾病建模的启示

Langston, Rebekah G; Rudenko, Iakov N; Cookson, Mark R

Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications

富亮氨酸重复激酶2突变的异质性:遗传学、机制和治疗意义

Rudenko, Iakov N; Cookson, Mark R

Hexokinase activity is required for recruitment of parkin to depolarized mitochondria

己糖激酶活性是帕金蛋白募集到去极化线粒体所必需的。

McCoy, Melissa K; Kaganovich, Alice; Rudenko, Iakov N; Ding, Jinhui; Cookson, Mark R

mRNA expression, splicing and editing in the embryonic and adult mouse cerebral cortex

小鼠胚胎和成年大脑皮层中的mRNA表达、剪接和编辑

Dillman, Allissa A; Hauser, David N; Gibbs, J Raphael; Nalls, Michael A; McCoy, Melissa K; Rudenko, Iakov N; Galter, Dagmar; Cookson, Mark R

Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?

抑制激酶活性是治疗 LRRK2 相关帕金森病的唯一治疗策略吗?

Rudenko, Iakov N; Chia, Ruth; Cookson, Mark R

The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation.

与帕金森病相关的富亮氨酸重复激酶 2 的 G2385R 变体是一种部分功能丧失突变

Rudenko Iakov N, Kaganovich Alice, Hauser David N, Beylina Aleksandra, Chia Ruth, Ding Jinhui, Maric Dragan, Jaffe Howard, Cookson Mark R